Abstract
We modified amylin chemically by conjugating methoxyl polyethyleneglycol succinimidyl carbonate (mPEGSC) of varying molecular weights (1 kDa, 2 kDa and 5 kDa). The reaction occurred within a few minutes, resulting in at least four distinct PEGylated products. The reaction products were separated by reversed-phase chromatography and identified by mass-spectrometry. The monoPEGylated and diPEGylated amylin products were generated rapidly through conjugation to the two amino groups of the N-terminal lysine residue. Both PEGylated amylin products bound to the receptor activity-modifying protein 1 (RAMP1). Pharmacological evaluation by subcutaneous administration in mice of monoPEGylated and diPEGylated amylin obtained with mPEG-SC 5 kDa revealed that both compounds modulated glycemia for longer times than unmodified amylin. Collectively, these data demonstrate the potential of bioconjugation with mPEG for the design of amylin therapeutics with sustained action.
Keywords: Amylin, diabetes, glycemia, islet associated polypeptide, PEGylation.
Protein & Peptide Letters
Title:Amylin Conjugation with Methoxyl Polyethyleneglycol
Volume: 20 Issue: 11
Author(s): Mariana F. A. N. Guterres, Luiz Henrique Guerreiro, Bruno Melo-Ferreira, Luiza C. S. Erthal and Luís Maurício T. R. Lima
Affiliation:
Keywords: Amylin, diabetes, glycemia, islet associated polypeptide, PEGylation.
Abstract: We modified amylin chemically by conjugating methoxyl polyethyleneglycol succinimidyl carbonate (mPEGSC) of varying molecular weights (1 kDa, 2 kDa and 5 kDa). The reaction occurred within a few minutes, resulting in at least four distinct PEGylated products. The reaction products were separated by reversed-phase chromatography and identified by mass-spectrometry. The monoPEGylated and diPEGylated amylin products were generated rapidly through conjugation to the two amino groups of the N-terminal lysine residue. Both PEGylated amylin products bound to the receptor activity-modifying protein 1 (RAMP1). Pharmacological evaluation by subcutaneous administration in mice of monoPEGylated and diPEGylated amylin obtained with mPEG-SC 5 kDa revealed that both compounds modulated glycemia for longer times than unmodified amylin. Collectively, these data demonstrate the potential of bioconjugation with mPEG for the design of amylin therapeutics with sustained action.
Export Options
About this article
Cite this article as:
F. A. N. Guterres Mariana, Guerreiro Henrique Luiz, Melo-Ferreira Bruno, S. Erthal C. Luiza and T. R. Lima Maurício Luís, Amylin Conjugation with Methoxyl Polyethyleneglycol, Protein & Peptide Letters 2013; 20 (11) . https://dx.doi.org/10.2174/09298665113209990067
DOI https://dx.doi.org/10.2174/09298665113209990067 |
Print ISSN 0929-8665 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5305 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Effect of Simvastatin use on Autonomic Function in Patients with End Stage Renal Disease
Cardiovascular & Hematological Disorders-Drug Targets Molecular Basis of Antiretroviral Drugs-Associated Long-Term Toxicity: How Bad can Good Drugs Be?
Current Medicinal Chemistry - Anti-Infective Agents Cardiovascular Effects of Phosphodiesterase 5 Inhibitors
Current Pharmaceutical Design Evaluation of Oxidative Status with Exhaled Breath 8-isoprostane Levels in Patients with Hyperthyroidism
Endocrine, Metabolic & Immune Disorders - Drug Targets Role of Polymorphisms in Factor V (FV Leiden), Prothrombin, Plasminogen Activator Inhibitor Type-1 (PAI-1), Methylenetetrahydrofolate Reductase (MTHFR) and Cystathionine β-Synthase (CBS) Genes as Risk Factors for Thrombophilias
Mini-Reviews in Medicinal Chemistry Biology of Circulating Nucleic Acids and Possible Roles in Diagnosis and Treatment in Diabetes and Cancer
Infectious Disorders - Drug Targets Communication from Tubular Epithelial Cells to Podocytes through Sirt1 and Nicotinic Acid Metabolism
Current Hypertension Reviews Management of Dyslipidemia in the Metabolic Syndrome
Cardiovascular & Hematological Disorders-Drug Targets Cerebral Arachidonate Cascade in Dementia: Alzheimers Disease and Vascular Dementia
Current Neuropharmacology Metformin, A New Era for an Old Drug in the Treatment of Immune Mediated Disease?
Current Drug Targets Polyphenols: Potential Future Arsenals in the Treatment of Diabetes
Current Pharmaceutical Design Pneumococcal Infections at Hajj: Current Knowledge Gaps
Infectious Disorders - Drug Targets Effect of the Interaction Between Hypertension and Cerebral White Matter Changes on the Progression of Alzheimer Disease
Current Alzheimer Research Controlled and Continuous Release Ocular Drug Delivery Systems: Pros and Cons
Current Drug Delivery Sirtuins and Resveratrol-Derived Compounds: A Model for Understanding the Beneficial Effects of the Mediterranean Diet
Endocrine, Metabolic & Immune Disorders - Drug Targets Recent Developments in Patents Targeting Toll-Like Receptor Genes
Recent Patents on DNA & Gene Sequences Cytochromes P450 in the Bioactivation of Chemicals
Current Topics in Medicinal Chemistry Editorial [ Reducing Cardiovascular Risk: Is Low-Density Lipoprotein-Cholesterol (LDL-C) Lowering Enough? ]
Current Vascular Pharmacology The HCMV Chemokine Receptor US28 is a Potential Target in Vascular Disease
Current Drug Targets - Infectious Disorders Quercetin in Cancer Treatment, Alone or in Combination with Conventional Therapeutics?
Current Medicinal Chemistry